Pinealon

Overview

Pinealon is a synthetic tripeptide consisting of glutamic acid, aspartic acid, and arginine (Glu-Asp-Arg). It was developed by the St. Petersburg Institute for Bioregulation and Gerontology under Vladimir Khavinson, the same research group that developed Epitalon. It is based on the amino acid composition of pineal gland extract and intended as a minimal biologically active unit of pineal-specific peptide bioregulation.

Pinealon is described in the scientific literature as a neuroprotective and geroprotective peptide. In animal models, cell cultures and one small human observational study it has been associated with anabolic effects on the central nervous system and with a slowing of biological aging markers in patients with organic brain syndrome. The research base originates predominantly from the Russian Khavinson group and requires careful interpretation.

The relationship with Epitalon is relevant for understanding Pinealon. Both peptides are derived from the pineal gland: Epitalon as a tetrapeptide (AEDG), Pinealon as a tripeptide (EDR). They share overlapping biological targets but have independent research trajectories. Where Epitalon has been primarily studied via telomere elongation and melatonin pathways, Pinealon research focuses more on neuroprotection and brain aging.

As with many compounds in the Khavinson tradition: the evidence is broader than a single study (animal, cell and biochemical data exist), but remains preclinical in centre of gravity, with only one small human observational study and without independent replication outside the original research tradition.

Mechanism of action

Pinealon's proposed neuroprotective effects are attributed to regulation of gene expression in nerve cells. The working model does not rest on a classical receptor, but on direct binding of the small peptide to DNA and to histones. Histones are the proteins around which DNA is wound; binding to them can influence the accessibility of genes. This epigenetic model is comparable to that proposed for Epitalon.

Proposed DNA and histone binding

• In biochemical experiments the EDR peptide bound to histones (H1, H2B, H3, H4) and to histone–DNA complexes in a site-specific manner (Fedoreyeva 2013).
• Binding is proposed at GC-rich motifs in promoter regions, consistent with a sequence-specific regulatory model rather than classical receptor activation.
• The model is mechanistically coherent across studies but has not been directly confirmed in humans.

Neuroprotection in preclinical models

• In rat offspring exposed prenatally to elevated homocysteine, administration of Pinealon to the pregnant dam improved later cognition and spatial orientation and reduced ROS accumulation and necrosis in cerebellar neurons (Arutjunyan 2012).
• In aging cell cultures of the cerebral cortex, the EDR peptide stimulated serotonin expression; docking pointed to the tryptophan hydroxylase gene (Khavinson 2014).
• These findings support a neuroprotective signal in models, not an established clinical effect.

Interpretive caution

• Published Pinealon-specific data are concentrated in and around one research tradition.
• No interventional human trial has tested Pinealon on its own; the single human study is observational and combined Pinealon with Vesugen.
• The proposed DNA/histone binding mechanism remains a model, not a confirmed in-human conclusion.

Research findings

• In rat offspring exposed prenatally to elevated homocysteine, Pinealon given to the pregnant dam improved later cognition and spatial orientation and reduced ROS accumulation and necrosis in cerebellar neurons (Arutjunyan 2012)
• In aging cerebral-cortex cell cultures, the EDR peptide stimulated serotonin expression; docking pointed to the tryptophan hydroxylase gene (Khavinson 2014)
• In biochemical experiments the EDR peptide bound site-specifically to histones (H1, H2B, H3, H4) and to histone–DNA complexes, supporting the proposed epigenetic mechanism (Fedoreyeva 2013)
• In an observational study of 32 patients with polymorbidity and organic brain syndrome, Pinealon and Vesugen showed anabolic and geroprotective effects, with Vesugen stronger; no effect on chromatin condensation was observed (Meshchaninov 2015)

Preclinical findings (animal, cell, biochemistry)

• In rat offspring exposed prenatally to elevated homocysteine, administration of Pinealon to the pregnant dam improved later cognition and spatial orientation and made cerebellar neurons more resistant to oxidative stress (Arutjunyan 2012). Oxidative stress is damage by reactive oxygen species.
• In aging cerebral-cortex cell cultures, the EDR peptide stimulated serotonin expression; molecular docking pointed to the gene for tryptophan hydroxylase, the enzyme that produces serotonin (Khavinson 2014).
• In biochemical experiments the EDR peptide bound to histones (H1, H2B, H3, H4) and to histone–DNA complexes in a site-specific manner. This supports the proposed epigenetic mechanism (Fedoreyeva 2013).

Clinical observations

• Anabolic effects on CNS and vital organs in patients with organic brain syndrome
• Slowing of biological aging measured via biological age indicators
• No effect on chromatin condensation in the studied population

Caveats and limitations

• Study comprised only 32 patients without a randomized control group
• Prooxidant activity observed; clinical relevance unclear
• Vesugen showed stronger geroprotective effects than Pinealon in the same study
• All published Pinealon-specific data come from a single research tradition

Research context

Pinealon sits in a preclinical foundation phase, with a limited and concentrated evidence base. The available data come from the Khavinson group in St. Petersburg, a productive but also controversial tradition in peptide bioregulation. The findings are internally consistent but lack independent international replication.

The relationship with Epitalon provides some indirect support: the shared pineal gland origin and overlapping biological targets suggest mechanistic plausibility. But this is not evidence for Pinealon specifically.

For those studying the Khavinson peptide tradition, Pinealon is a logical complementary compound alongside Epitalon. The evidence is broader than a single study (animal, cell and biochemical data exist), but remains preclinical in centre of gravity, with only one small human observational study and without independent replication outside the original research tradition.

Open questions

Pinealon has an interesting profile within the Khavinson peptide bioregulation tradition, but the evidence base is preclinical in centre of gravity and concentrated in one tradition. Independent studies are needed to validate the findings.

• Human evidence is limited to one small observational study (32 patients, non-randomized); there is no randomized controlled trial and no interventional human research that tests Pinealon on its own
• All Pinealon-specific data come from a single research tradition; no independent replication
• The proposed DNA/histone binding mechanism has not been directly confirmed in humans
• Pharmacokinetic profile in humans completely unknown
• Prooxidant activity observed but clinical relevance unclear
• Long-term safety profile not established

Research outlook

Independent replication studies are the priority next step

Comparative studies with Epitalon can clarify differential effects

Molecular mechanism studies can test the epigenetic hypothesis

Combination studies with other neuroprotective peptides are logical given the shared research domain

Scientific interest

Pineal regulation

Cognitive aging

Neuroprotection

Khavinson tradition

Specifications

References

1. Peptides and Ageing. · Khavinson VKh. · Neuro Endocrinology Letters · 2002
2. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. · Arutjunyan A, Kozina L, Stvolinskiy S, et al. · Int J Clin Exp Med · 2012
3. Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides. · Fedoreyeva LI, Smirnova TA, Kolomijtseva GYa, Khavinson VKh, Vanyushin BF · Biochemistry (Mosc) · 2013
4. Short peptides stimulate serotonin expression in cells of brain cortex. · Khavinson VKh, Lin'kova NS, Tarnovskaya SI, et al. · Bull Exp Biol Med · 2014
5. Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome. · Meshchaninov VN, Tkachenko EL, Zharkov SV, et al. · Advances in Gerontology · 2015
6. Identification of Peptide AEDG in the Polypeptide Complex of the Pineal Gland. · Khavinson VKh, Kopylov AT, Vaskovsky BV, et al. · Bulletin of Experimental Biology and Medicine · 2017

Availability

In stock · Batch PEP-PIN-2025-01 · HPLC 99.17 % · released 21 Jun 2026

• Pinealon 10 mg · product page with price and batch CoA